
## **Christian Furth**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9686770/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pindborg Tumor—An Uncommon Odontogenic Tumor Detected by 68Ga-DOTATOC. Diagnostics, 2022, 12, 389.	2.6	1
2	Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients. Frontiers in Oncology, 2022, 12, 879089.	2.8	2
3	A convolutional neural network for fully automated blood SUV determination to facilitate SUR computation in oncological FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 995-1004.	6.4	6
4	The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. Cancers, 2021, 13, 635.	3.7	10
5	Comparison of diagnostic value of 68ÂGa-DOTATOC PET/MRI and standalone MRI for the detection of intracranial meningiomas. Scientific Reports, 2021, 11, 9064.	3.3	10
6	Respiratory motion correction for enhanced quantification of hepatic lesions in simultaneous PET and DCE-MR imaging. Physics in Medicine and Biology, 2021, 66, 095012.	3.0	8
7	Granulomatous large vessel phlebitis in sarcoidosis. Rheumatology, 2021, 60, e432-e434.	1.9	0
8	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.7	2
9	FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. Lung Cancer, 2021, 157, 66-74.	2.0	6
10	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	2.0	16
11	Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score. Cancers, 2021, 13, 3777.	3.7	5
12	68Ga-DOTATOC-PET/MRI—A Secure One-Stop Shop Imaging Tool for Robotic Radiosurgery Treatment Planning in Patients with Optic Nerve Sheath Meningioma. Cancers, 2021, 13, 3305.	3.7	5
13	Added Value of Tomoelastography for Characterization of Pancreatic Neuroendocrine Tumor Aggressiveness Based on Stiffness. Cancers, 2021, 13, 5185.	3.7	8
14	First Report of Glioblastoma and Associated PNKP Mutation. Neuropediatrics, 2021, 52, .	0.6	0
15	Validation of Independent Prognostic Value of Asphericity of 18F-Fluorodeoxyglucose Uptake in Non–Small-Cell Lung Cancer Patients Undergoing Treatment With Curative Intent. Clinical Lung Cancer, 2020, 21, 264-272.e6.	2.6	3
16	Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?. Diagnostics, 2020, 10, 732.	2.6	7
17	68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer. PLoS ONE, 2020, 15, e0240892.	2.5	18
18	Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition. Diagnostics, 2020, 10, 1084.	2.6	3

CHRISTIAN FURTH

#	Article	IF	CITATIONS
19	Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (Q.Clear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF). EJNMMI Physics, 2020, 7, 2.	2.7	39
20	PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study. F1000Research, 2020, 9, 1350.	1.6	3
21	Asphericity of tumor FDG uptake in non-small cell lung cancer: reproducibility and implications for harmonization in multicenter studies. EJNMMI Research, 2020, 10, 134.	2.5	2
22	Title is missing!. , 2020, 15, e0240892.		0
23	Title is missing!. , 2020, 15, e0240892.		0
24	Title is missing!. , 2020, 15, e0240892.		0
25	Title is missing!. , 2020, 15, e0240892.		0
26	Iterative CT reconstruction in abdominal low-dose CT used for hybrid SPECT-CT applications: effect on image quality, image noise, detectability, and reader's confidence. Acta Radiologica Open, 2019, 8, 205846011985626.	0.6	10
27	The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. PLoS ONE, 2019, 14, e0216781.	2.5	14
28	Prostate-Specific Membrane Antigen–Positive Manifestations of Chronic Beryllium Lung Disease. Clinical Nuclear Medicine, 2019, 44, 64-65.	1.3	3
29	Point Spread Function Reconstruction for Integrated 18F-FET PET/MRI in Patients With Glioma. Clinical Nuclear Medicine, 2019, 44, e280-e285.	1.3	5
30	Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution. Neurosurgical Focus, 2019, 46, E9.	2.3	23
31	Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1752-1761.	6.4	8
32	l-123-MIBG scintigraphy in patients with neuroblastoma. Nuklearmedizin - NuclearMedicine, 2018, 57, 35-39.	0.7	2
33	Image Quality Assessment for Low-Dose-CT in Hybrid SPECT/CT Imaging. Nuklearmedizin - NuclearMedicine, 2018, 57, 153-159.	0.7	6
34	Local ablative treatment for synchronous single organ oligometastatic lung cancer—A propensity score analysis of 180 patients. Lung Cancer, 2018, 125, 164-173.	2.0	27
35	Gaâ€68â€PSMA PET/CT in treatmentâ€naÃ⁻ve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMAâ€positive metastases?. Prostate, 2018, 78, 1103-1110.	2.3	15
36	68 Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer. Cancer Imaging, 2018, 18, 20.	2.8	22

CHRISTIAN FURTH

#	Article	IF	CITATIONS
37	Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma. BMC Cancer, 2018, 18, 521.	2.6	39
38	Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBC SPECT predict the outcome?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2203-2212.	6.4	2
39	Detection of obstructive uropathy and assessment of differential renal function using two functional magnetic resonance urography tools. Nuklearmedizin - NuclearMedicine, 2017, 56, 39-46.	0.7	6
40	Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. Radiation Oncology, 2017, 12, 140.	2.7	34
41	The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2360-2373.	6.4	46
42	Standardized visual reading of F18-FDG-PET in patients with non-small cell lung cancer scheduled for preoperative thoracic lymph node staging. European Journal of Radiology, 2016, 85, 1345-1350.	2.6	10
43	Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms. Journal of Nuclear Medicine, 2016, 57, 180-185.	5.0	6
44	Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients. European Radiology, 2016, 26, 2808-2818.	4.5	10
45	The association of tumor-to-background ratios and SUVmax deviations related to point spread function and time-of-flight F18-FDG-PET/CT reconstruction in colorectal liver metastases. EJNMMI Research, 2015, 5, 31.	2.5	29
46	Time Course of Contrast Enhancement by Micro-CT with Dedicated Contrast Agents in Normal Mice and Mice with Hepatocellular Carcinoma. Academic Radiology, 2015, 22, 169-178.	2.5	26
47	FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value. Cancers, 2015, 7, 287-304.	3.7	22
48	Intrahepatic Activity Distribution in Radioembolization with Yttrium-90–Labeled Resin Microspheres Using the Body Surface Area Method—A Less than Perfect Model. Journal of Vascular and Interventional Radiology, 2015, 26, 1615-1621.	0.5	24
49	Optimization of SPECT-CT Hybrid Imaging Using Iterative Image Reconstruction for Low-Dose CT: A Phantom Study. PLoS ONE, 2015, 10, e0138658.	2.5	15
50	Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer, 2014, 14, 896.	2.6	40
51	The influence of different signal-to-background ratios on spatial resolution and F18-FDG-PET quantification using point spread function and time-of-flight reconstruction. EJNMMI Physics, 2014, 1, 12.	2.7	36
52	Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients. EJNMMI Research, 2013, 3, 71.	2.5	9
53	Influence of rigid coregistration of PET and CT data on metabolic volumetry: a user's perspective. EJNMMI Research, 2013, 3, 85.	2.5	Ο
54	Predictive Value of Intratumoral <sup>99m</sup> Tc-Macroaggregated Albumin Uptake in Patients with Colorectal Liver Metastases Scheduled for Radioembolization with <sup>90</sup> Y-Microspheres. Journal of Nuclear Medicine, 2013, 54, 516-522.	5.0	81

CHRISTIAN FURTH

#	Article	IF	CITATIONS
55	Quantification in <sup>68</sup> Ga-DOTA(0)-Phe(1)-Tyr(3)-Octreotide Positron Emission Tomography/Computed Tomography: Can We Be Impartial about Partial Volume Effects?. Neuroendocrinology, 2013, 97, 369-374.	2.5	13
56	SUVâ€measurements and patientâ€specific corrections in pediatric Hodgkinâ€lymphoma: Is there a benefit for PPV in early response assessment by FDGâ€PET?. Pediatric Blood and Cancer, 2012, 59, 475-480.	1.5	15
57	Blinded-Read of Bone Scintigraphy. Clinical Nuclear Medicine, 2011, 36, 186-191.	1.3	30
58	<sup>68</sup> Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol. Journal of Nuclear Medicine, 2011, 52, 697-704.	5.0	89
59	Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1842-1853.	6.4	105
60	The role of PET in Hodgkin's lymphoma and its impact on radiation oncology. Expert Review of Anticancer Therapy, 2010, 10, 1419-1428.	2.4	9
61	Early and Late Therapy Response Assessment With [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial. Journal of Clinical Oncology, 2009, 27, 4385-4391.	1.6	150
62	Attenuation Correction of Somatostatin Receptor SPECT by Integrated Low-Dose CT. Clinical Nuclear Medicine, 2009, 34, 869-873.	1.3	11
63	Use of positron emission tomography for staging, preoperative response assessment and posttherapeutic evaluation in children with Wilms tumour. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1642-1650.	6.4	49
64	Positron Emission Tomography for Staging of Pediatric Sarcoma Patients: Results of a Prospective Multicenter Trial. Journal of Clinical Oncology, 2007, 25, 5435-5441.	1.6	372
65	Correlative Imaging Strategies Implementing CT, MRI, and PET for Staging of Childhood Hodgkin Disease. Journal of Pediatric Hematology/Oncology, 2006, 28, 501-512.	0.6	57